Q32 Bio Hires Trevejo as Chief Medical Officer — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Q32 Bio hired José Trevejo as chief medical officer, featured as the highlighted move in STAT+'s recurring "Up and down the ladder" personnel column.
- Trevejo previously served as chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics, giving him direct experience running clinical pipelines at an AI-driven drug discovery company.
- STAT+ frames the column as an open call, inviting companies to submit their own comings-and-goings announcements for publication alongside its weekly staff pick.
- The remainder of this week's personnel moves — beyond the Trevejo spotlight — sits behind the STAT+ paywall and is not visible in the excerpt.
- Q32 Bio is a clinical-stage biotech focused on inflammation and autoimmune disease, the type of pipeline-stage company where a CMO hire signals active trial execution rather than discovery work.
Why it matters: Q32 Bio adds a clinical leader with prior CMO and pipeline-strategy experience at Enveda Therapeutics, signaling that the company is staffing up for active trial execution rather than early-stage discovery. The hire also illustrates how STAT+'s weekly column doubles as a low-cost hiring announcement channel for biotechs willing to share the news.
Ask SkimNews